DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1-20 were originally filed August 8, 2024.
Claims 1-20 are currently pending.
Claims 1 and 15 are currently under consideration.
Election/Restrictions
Applicant's election with traverse of Group I (claims 1-17) in the reply filed on October 6, 2026 is acknowledged. The traversal is on the grounds that elected Group I is utilized in the non-elected method of Group II, therefore, any prior art searched for the elected Group I would be applicable to the method of Group II. This is not found persuasive because Groups I and II are related as a product and a process of utilizing the product. The Groups can be shown to be distinct if either or both of the following can be shown: (1) the process for utilizing the product as claimed can be practiced with another materially different product or (2) the product as claimed can be utilized in a materially different process of utilizing that product. See MPEP § 806.05(h). In the instant case, the process for utilizing the product as claimed can be practiced with another materially different product (any FDA approved treatment for any proliferative disease including cancer and PAH). In addition, the product can be utilized in a different process (a method of screening for binding). In addition, there is a serious search burden because, the product and the method have acquired a separate status in the art in view of the different classification (C07K 7/00 and A61K 38/00), the product and method have acquired a separate status in the art due to the recognized divergent subject matter, the product and metho require a different field of search, and/or the product and the method are likely to raise different non-prior art issues under 35 USC 101 and/or 35 USC 112.
The requirement is still deemed proper and is therefore made FINAL.
Claims 18-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected method, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on October 6, 2026.
Applicant’s election of SEQ ID NO: 1, inhibiting the interaction between IMPA1 and RAGE, SEQ ID NO: 36 as the species in the reply filed on October 6, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
Please note: elections should be definitive in nature (i.e. utilization of “e.g., IL”, “e.g., amidation” are not definitive elections). In addition, utilization of D amino acids and amidation for stability is well-known, routine, and conventional in the prior art.
Please note: applicants appear to be of the opinion that SEQ ID NO: 36 has two N-terminal D amino acids and C-terminal amination. However, SEQ ID NO: 36 of the present sequence listing is a duplicate of SEQ ID NO: 1. SEG ID NO: 36 of the present sequence listing does not designate any amino acids to be in D form and SEQ ID NO: 36 does not designate a C-terminal amide.
Claims 2-14, 16, and 17 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on October 6, 2026.
Potential Rejoinder
Applicant elected claims directed to a product. If a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.
In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all the criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See “Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b),” 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to a rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.
Priority
The present application claims status as a CIP of PCT/US23/14131 filed February 28, 2023 which claims the benefit of 63/314,883.
Please note: PCT/US23/14131 contains 34 sequences (SEQ ID NOs: 1-34) while the present application contains 40 sequences (SEQ ID NOs: 1-40). Therefore, present claim 15 has an effective filing date of August 8, 2024.
Information Disclosure Statement
The information disclosure statement filed October 18, 2024 fails to comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609 because the citations are incomplete (e.g. missing date, missing journal, missing volume number, etc.; see the marked up IDS). It has been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicant is advised that the date of any re-submission of any item of information contained in this information disclosure statement or the submission of any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the statement, including all certification requirements for statements under 37 CFR 1.97(e). See MPEP § 609.05(a).
Specification
The disclosure is objected to because of the following informalities: SEQ ID NOs: 1 and 36 are identical.
Appropriate correction is required.
Sequence Interpretation
The Office interprets claims comprising SEQ ID NOs: in the following manner: “comprising a sequence of SEQ ID NO: 1” requires only a 2mer of SEQ ID NO: 1, “comprising the sequence of SEQ ID NO: 1” requires the full-length sequence with 100% identity to SEQ ID NO: 1 with any N-/C-terminal additions or any 5’/3’ additions, “consisting of SEQ ID NO: 1” requires the full-length sequence with 100% identity to SEQ ID NO: 1 and the same length as SEQ ID NO: 1, and “selected from the group consisting of SEQ ID NOs: 1, 2, and 3” requires the full-length sequence with 100% identity to SEQ ID NOs: 1, 2, or 3 and the same length as SEQ ID NOs: 1, 2, or 3. Any claim requiring a specific percent identity, necessarily requires at least the recited percent identity.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 15 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 15 is dependent on independent claim 1. Independent claim 1 requires SEQ ID NO: 1 (ILWQRRQRRG). Dependent claim 15 requires SEQ ID NO: 36 which is a duplicate of SEQ ID NO: 1. Therefore, SEQ ID NO: 36 fails to further limit SEQ ID NO: 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1 and 15 are rejected under 35 U.S.C. 101 because the claimed invention is directed to peptide fragments of the polypeptide RAGE without significantly more. The claims recite SEQ ID NO: 1 (ILWQRRQRRG), SEQ ID NO: 2 (ILWQRRQRRGEERKAP), and SEQ ID NO: 36 (same as SEQ ID NO: 1). This judicial exception is not integrated into a practical application because the claims are drawn to a product. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the claims are drawn to the peptide fragment only.
SEQ ID NOs: 1 and 36
RESULT 1
Q9UQR5_HUMAN
ID Q9UQR5_HUMAN Unreviewed; 82 AA.
AC Q9UQR5;
DT 01-MAY-2000, integrated into UniProtKB/TrEMBL.
DT 01-MAY-2000, sequence version 1.
DT 28-JAN-2026, entry version 76.
DE SubName: Full=Receptor for advanced glycosylation end product {ECO:0000313|EMBL:CAB43094.1};
DE Flags: Fragment;
GN Name=RAGE {ECO:0000313|EMBL:CAB43094.1};
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606 {ECO:0000313|EMBL:CAB43094.1};
RN [1] {ECO:0000313|EMBL:CAB43094.1}
RP NUCLEOTIDE SEQUENCE.
RA Kankova K.;
RL Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AJ238896; CAB43094.1; -; Genomic_DNA.
DR AlphaFoldDB; Q9UQR5; -.
DR PeptideAtlas; Q9UQR5; -.
PE 4: Predicted;
KW Membrane {ECO:0000256|SAM:Phobius}; Receptor {ECO:0000313|EMBL:CAB43094.1};
KW Transmembrane {ECO:0000256|SAM:Phobius};
KW Transmembrane helix {ECO:0000256|SAM:Phobius}.
FT TRANSMEM 20..41
FT /note="Helical"
FT /evidence="ECO:0000256|SAM:Phobius"
FT REGION 45..82
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 56..74
FT /note="Acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT NON_TER 1
FT /evidence="ECO:0000313|EMBL:CAB43094.1"
SQ SEQUENCE 82 AA; 8423 MW; 06D81F3634AD38F8 CRC64;
Query Match 100.0%; Score 55; Length 82;
Best Local Similarity 100.0%;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ILWQRRQRRG 10
||||||||||
Db 39 ILWQRRQRRG 48
SEQ ID NO: 2
RESULT 1
Q9UQR5_HUMAN
ID Q9UQR5_HUMAN Unreviewed; 82 AA.
AC Q9UQR5;
DT 01-MAY-2000, integrated into UniProtKB/TrEMBL.
DT 01-MAY-2000, sequence version 1.
DT 28-JAN-2026, entry version 76.
DE SubName: Full=Receptor for advanced glycosylation end product {ECO:0000313|EMBL:CAB43094.1};
DE Flags: Fragment;
GN Name=RAGE {ECO:0000313|EMBL:CAB43094.1};
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606 {ECO:0000313|EMBL:CAB43094.1};
RN [1] {ECO:0000313|EMBL:CAB43094.1}
RP NUCLEOTIDE SEQUENCE.
RA Kankova K.;
RL Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AJ238896; CAB43094.1; -; Genomic_DNA.
DR AlphaFoldDB; Q9UQR5; -.
DR PeptideAtlas; Q9UQR5; -.
PE 4: Predicted;
KW Membrane {ECO:0000256|SAM:Phobius}; Receptor {ECO:0000313|EMBL:CAB43094.1};
KW Transmembrane {ECO:0000256|SAM:Phobius};
KW Transmembrane helix {ECO:0000256|SAM:Phobius}.
FT TRANSMEM 20..41
FT /note="Helical"
FT /evidence="ECO:0000256|SAM:Phobius"
FT REGION 45..82
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 56..74
FT /note="Acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT NON_TER 1
FT /evidence="ECO:0000313|EMBL:CAB43094.1"
SQ SEQUENCE 82 AA; 8423 MW; 06D81F3634AD38F8 CRC64;
Query Match 100.0%; Score 86; Length 82;
Best Local Similarity 100.0%;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ILWQRRQRRGEERKAP 16
||||||||||||||||
Db 39 ILWQRRQRRGEERKAP 54
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Belouchi et al. WO 2008/016356 published February 7, 2008.
For present claim 1, Belouchi et al. teach SEQ ID NO: 15019 which has 100% identity to present SEQ ID NO: 1 (please refer to the entire specification particularly SEQ ID NO: 15019).
Therefore, the teachings of Belouchi et al. anticipate the presently claimed peptide.
Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chakraborty et al. U.S. Patent 9,220,755 issued December 29, 2015.
For present claim 1, Chakraborty et al. teach SEQ ID NO: 36856 which has 100% identity to present SEQ ID NO: 1 (please refer to the entire specification particularly SEQ ID NO: 36856).
Therefore, the teachings of Chakraborty et al. anticipate the presently claimed peptide.
Future Communications
Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMBER D STEELE whose telephone number is (571)272-5538. The examiner can normally be reached M-F 8-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/AMBER D STEELE/Primary Examiner, Art Unit 1658